United Therapeutics Corporation Employee Service Share-based Compensation, Cash Received from Exercise of Stock Options (Deprecated 2017-01-31)
United Therapeutics Corporation (UTHR) reported Employee Service Share-based Compensation, Cash Received from Exercise of Stock Options (Deprecated 2017-01-31) of $2.40 million for the 3-month period ending 2016-06-30, per its 10-Q filed 2016-07-28.
Discontinued › Notes › Compensation Related Costs
us-gaap:EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions · last filed 2016-07-28
- United Therapeutics Corporation employee service share-based compensation, cash received from exercise of stock options (deprecated 2017-01-31) for the quarter ending 2016-06-30 was $2.40M, a 83.22% decline year-over-year.
- United Therapeutics Corporation employee service share-based compensation, cash received from exercise of stock options (deprecated 2017-01-31) for the quarter ending 2016-03-31 was $2.60M, a 74.26% decline year-over-year.
- United Therapeutics Corporation employee service share-based compensation, cash received from exercise of stock options (deprecated 2017-01-31) for the quarter ending 2015-12-31 was $6.29M, a 41.62% decline year-over-year.
- United Therapeutics Corporation employee service share-based compensation, cash received from exercise of stock options (deprecated 2017-01-31) for the quarter ending 2015-09-30 was $8.57M, a 50.21% decline year-over-year.
- United Therapeutics Corporation employee service share-based compensation, cash received from exercise of stock options (deprecated 2017-01-31) for fiscal 2015 was $39.31M, a 21.64% decline from fiscal 2014.
- United Therapeutics Corporation employee service share-based compensation, cash received from exercise of stock options (deprecated 2017-01-31) for fiscal 2014 was $50.17M, a 88.47% increase from fiscal 2013.
- United Therapeutics Corporation employee service share-based compensation, cash received from exercise of stock options (deprecated 2017-01-31) for fiscal 2013 was $26.62M, a 86.28% increase from fiscal 2012.
- United Therapeutics Corporation employee service share-based compensation, cash received from exercise of stock options (deprecated 2017-01-31) for fiscal 2012 was $14.29M, a 41.43% decline from fiscal 2011.
| Period end | Employee Service Share-based Compensation, Cash Received from Exercise of Stock Options (Deprecated 2017-01-31) 3 month | Employee Service Share-based Compensation, Cash Received from Exercise of Stock Options (Deprecated 2017-01-31) 3 month as first filed | Employee Service Share-based Compensation, Cash Received from Exercise of Stock Options (Deprecated 2017-01-31) 6 month | Employee Service Share-based Compensation, Cash Received from Exercise of Stock Options (Deprecated 2017-01-31) 6 month as first filed | Employee Service Share-based Compensation, Cash Received from Exercise of Stock Options (Deprecated 2017-01-31) 9 month | Employee Service Share-based Compensation, Cash Received from Exercise of Stock Options (Deprecated 2017-01-31) 12 month | Employee Service Share-based Compensation, Cash Received from Exercise of Stock Options (Deprecated 2017-01-31) 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2016-06-30 | $2.40M 10-Q · filed 2016-07-28 | $5.00M 10-Q · filed 2016-07-28 | $11.29M derived: sum of 3 quarters · filed 2016-07-28 | $19.87M derived: sum of 4 quarters · filed 2016-07-28 | |||
| 2016-03-31 | $2.60M 10-Q · filed 2016-04-28 | $8.89M derived: sum of 2 quarters · filed 2016-04-28 | $17.47M derived: sum of 3 quarters · filed 2016-04-28 | $31.77M derived: sum of 4 quarters · filed 2016-07-28 | |||
| 2015-12-31 | $6.29M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25 | $14.87M derived: sum of 2 quarters · filed 2016-02-25 | $29.17M derived: sum of 3 quarters · filed 2016-07-28 | $39.31M 10-K · filed 2016-02-25 | |||
| 2015-09-30 | $8.57M 10-Q · filed 2015-10-27 | $22.87M derived: sum of 2 quarters · filed 2016-07-28 | $33.02M 10-Q · filed 2015-10-27 | $43.75M derived: sum of 4 quarters · filed 2016-07-28 | |||
| 2015-06-30 | $14.30M 10-Q · filed 2016-07-28 | $14.31M 10-Q · filed 2015-07-28 | $24.40M 10-Q · filed 2016-07-28 | $24.45M 10-Q · filed 2015-07-28 | $35.18M derived: sum of 3 quarters · filed 2016-07-28 | $52.40M derived: sum of 4 quarters · filed 2016-07-28 | |
| 2015-03-31 | $10.10M 10-Q · filed 2016-04-28 | $10.13M 10-Q · filed 2015-04-28 | $20.88M derived: sum of 2 quarters · filed 2016-04-28 | $38.10M derived: sum of 3 quarters · filed 2016-04-28 | $51.83M derived: sum of 4 quarters · filed 2016-04-28 | ||
| 2014-12-31 | $10.78M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25 | $28.00M derived: sum of 2 quarters · filed 2016-02-25 | $41.73M derived: sum of 3 quarters · filed 2016-02-25 | $50.17M 10-K · filed 2016-02-25 | |||
| 2014-09-30 | $17.22M 10-Q · filed 2015-10-27 | $30.96M derived: sum of 2 quarters · filed 2015-10-27 | $39.39M 10-Q · filed 2015-10-27 | $46.11M derived: sum of 4 quarters · filed 2016-02-25 | |||
| 2014-06-30 | $13.74M 10-Q · filed 2015-07-28 | $22.17M 10-Q · filed 2015-07-28 | $28.89M derived: sum of 3 quarters · filed 2016-02-25 | $38.69M derived: sum of 4 quarters · filed 2016-02-25 | |||
| 2014-03-31 | $8.43M 10-Q · filed 2015-04-28 | $15.16M derived: sum of 2 quarters · filed 2016-02-25 | $24.96M derived: sum of 3 quarters · filed 2016-02-25 | $30.79M derived: sum of 4 quarters · filed 2016-02-25 | |||
| 2013-12-31 | $6.72M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25 | $16.52M derived: sum of 2 quarters · filed 2016-02-25 | $22.36M derived: sum of 3 quarters · filed 2016-02-25 | $26.62M 10-K · filed 2016-02-25 | $26.62M 10-K · filed 2014-02-25 | ||
| 2013-09-30 | $9.80M 10-Q · filed 2014-10-28 | $15.64M derived: sum of 2 quarters · filed 2014-10-28 | $19.90M 10-Q · filed 2014-10-28 | $24.50M derived: sum of 4 quarters · filed 2015-02-24 | |||
| 2013-06-30 | $5.84M 10-Q · filed 2014-07-29 | $10.10M 10-Q · filed 2014-07-29 | $14.70M derived: sum of 3 quarters · filed 2015-02-24 | $21.27M derived: sum of 4 quarters · filed 2015-02-24 | |||
| 2013-03-31 | $4.26M 10-Q · filed 2014-04-29 | $8.86M derived: sum of 2 quarters · filed 2015-02-24 | $15.43M derived: sum of 3 quarters · filed 2015-02-24 | $16.74M derived: sum of 4 quarters · filed 2015-02-24 | |||
| 2012-12-31 | $4.60M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24 | $11.18M derived: sum of 2 quarters · filed 2015-02-24 | $12.48M derived: sum of 3 quarters · filed 2015-02-24 | $14.29M 10-K · filed 2015-02-24 | |||
| 2012-09-30 | $6.58M 10-Q · filed 2013-10-29 | $7.88M derived: sum of 2 quarters · filed 2013-10-29 | $9.69M 10-Q · filed 2013-10-29 | $10.14M derived: sum of 4 quarters · filed 2014-02-25 | |||
| 2012-06-30 | $1.30M 10-Q · filed 2013-07-25 | $3.11M 10-Q · filed 2013-07-25 | $3.56M derived: sum of 3 quarters · filed 2014-02-25 | $3.79M derived: sum of 4 quarters · filed 2014-02-25 | |||
| 2012-03-31 | $1.81M 10-Q · filed 2013-04-25 | $2.26M derived: sum of 2 quarters · filed 2014-02-25 | $2.48M derived: sum of 3 quarters · filed 2014-02-25 | $12.23M derived: sum of 4 quarters · filed 2014-02-25 | |||
| 2011-12-31 | $450.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | $674.00K derived: sum of 2 quarters · filed 2014-02-25 | $10.42M derived: sum of 3 quarters · filed 2014-02-25 | $24.40M 10-K · filed 2014-02-25 | |||
| 2011-09-30 | $224.00K 10-Q · filed 2012-11-01 | $9.97M derived: sum of 2 quarters · filed 2012-11-01 | $23.95M 10-Q · filed 2012-11-01 | $44.95M derived: sum of 4 quarters · filed 2013-02-26 | |||
| 2011-06-30 | $9.75M 10-Q · filed 2012-07-26 | $23.72M 10-Q · filed 2012-07-26 | $44.73M derived: sum of 3 quarters · filed 2013-02-26 | $54.55M derived: sum of 4 quarters · filed 2013-02-26 | |||
| 2011-03-31 | $13.98M 10-Q · filed 2012-04-26 | $34.98M derived: sum of 2 quarters · filed 2013-02-26 | $44.80M derived: sum of 3 quarters · filed 2013-02-26 | $63.08M derived: sum of 4 quarters · filed 2013-02-26 | |||
| 2010-12-31 | $21.00M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | $30.82M derived: sum of 2 quarters · filed 2013-02-26 | $49.10M derived: sum of 3 quarters · filed 2013-02-26 | $85.43M 10-K · filed 2013-02-26 | |||
| 2010-09-30 | $9.82M 10-Q · filed 2011-10-27 | $28.10M derived: sum of 2 quarters · filed 2011-10-27 | $64.42M 10-Q · filed 2011-10-27 | ||||
| 2010-06-30 | $18.28M 10-Q · filed 2011-07-28 | $54.60M 10-Q · filed 2011-07-28 | |||||
| 2009-12-31 | $32.61M 10-K · filed 2012-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |